Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

InMed Pharmaceuticals (INM) Depreciation Expense (2019 - 2025)

InMed Pharmaceuticals has reported Depreciation Expense over the past 4 years, most recently at $12206.0 for Q2 2025.

  • For Q2 2025, Depreciation Expense rose 124.37% year-over-year to $12206.0; the TTM value through Jun 2025 reached $50204.0, up 5.16%, while the annual FY2025 figure was $50204.0, 5.16% up from the prior year.
  • Depreciation Expense for Q2 2025 was $12206.0 at InMed Pharmaceuticals, roughly flat from $12203.0 in the prior quarter.
  • Over five years, Depreciation Expense peaked at $14242.0 in Q4 2023 and troughed at $5440.0 in Q2 2024.
  • A 4-year average of $11773.0 and a median of $12209.0 in 2024 define the central range for Depreciation Expense.
  • Biggest five-year swings in Depreciation Expense: tumbled 57.88% in 2024 and later soared 124.37% in 2025.
  • Year by year, Depreciation Expense stood at $8056.0 in 2022, then skyrocketed by 76.79% to $14242.0 in 2023, then dropped by 14.27% to $12209.0 in 2024, then dropped by 0.02% to $12206.0 in 2025.
  • Business Quant data shows Depreciation Expense for INM at $12206.0 in Q2 2025, $12203.0 in Q1 2025, and $12209.0 in Q4 2024.